Point72 Asset Management L.P. Sells 451,600 Shares of ABIVAX Société Anonyme (NASDAQ:ABVX)

Point72 Asset Management L.P. lessened its stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 83.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,300 shares of the company's stock after selling 451,600 shares during the quarter. Point72 Asset Management L.P. owned about 0.14% of ABIVAX Société Anonyme worth $668,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Kennedy Capital Management LLC boosted its holdings in ABIVAX Société Anonyme by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock worth $1,650,000 after purchasing an additional 1,656 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after buying an additional 1,990 shares during the period. R Squared Ltd purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth $36,000. BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 47.5% during the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company's stock valued at $141,000 after acquiring an additional 6,200 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in ABIVAX Société Anonyme during the fourth quarter valued at $85,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ ABVX traded down $0.01 during midday trading on Wednesday, reaching $5.68. The stock had a trading volume of 55,196 shares, compared to its average volume of 139,911. ABIVAX Société Anonyme has a 12-month low of $4.77 and a 12-month high of $14.71. The stock has a 50-day moving average of $6.32 and a 200-day moving average of $7.02.

Wall Street Analyst Weigh In

ABVX has been the topic of several research reports. JMP Securities reissued a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.